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ABSTRACT 
Two experiments were conducted to determine the effects of immunoneutralization of growth 
hormone-releasing factor [GRF(1-29)-NH2] on concentrations of somatotropin (ST) and insulin-like 
growth factor I (IGF-I) in lactating beef cows. In Experiment 1, mUltiparous Hereford cows were 
immunized against 2 mg GRF(l-29)-(GlY)4-Cys-NH2 conjugated to human serum albumin (GRFi, 
n=3) or 2 mg human serum albumin (HSAi, n=3) at 52 ± 1 d prior to parturition. Boosters (1 mg) 
were administered on days 12,40 and 114 postpartum (pp). Serum samples were collected at IS-min 
intervals for 5 hr on days 18,46 and 120 pp, followed by administration CIV) of an opioid agonist 
(FK33-824; 10 J..lg/kg) and an antagonist (naloxone; .5 mg/kg) at hours 5 and 7, respectively. A GRF­
analog ([desamino-Tyrl, D-Ala2 , Alal5] GRF (l-29)-NH2; 3.5 ~lkg) and arginine (.5 glkg) were 
administered at hour 10 on days 47 and 121, respectively. Percentage binding of [125I]GRF (1:100 
dilution of serum) 28 d after primary immunization was greater in GRFi (14.3 ± 4.9) than in HSAi 
(.7 ± .3) cows. Binding increased to 29.3 ± 6.5% after first booster in GRFi cows. Episodic release 
of ST was abolished by immunization against GRF; concentration and frequency of release of ST 
were lower (P<.05) in GRFi than in HSAi cows on all days pp. Concentrations of IGF-I were lower 
in GRFi than in HSAi cows throughout lactation. Serum ST failed to increase following FK33-824 
or arginine in GRFi; however, ST increased after both compounds in HSAi cows. Concentrations of 
ST following GRF-analog were greater (P<.05) in HSAi than in GRFi cows. Experiment 2 was con­
ducted to determine if a lower dose of antigen and a single booster would be sufficient to lower ST 
and IGF-I in lactating cows. Multiparous Hereford and Angus cows were assigned to GRFi (n=6) 
or HSAi (n=6). Primary (1.2 mg) and booster (.5 mg) immunizations were administered -14 and 8 
d from calving, respectively. Cows were restricted to 60% of recommended intake of energy dur­
ing lactation in order to elevate concentrations of ST. Serum samples were collected at IS-min in­
tervals for 6 hr on days 26, 50, 73, 90 and 109 pp. Two of six GRFi cows had binding less than 10% 
(1 : 1 ,000 dilution of serum) and were omitted from further analyses. Percentage binding at a I: 1,000 
dilution was greater in GRFi (17.0 ± 4.7) than in HSAi (1.4 ± .4) cows at 89 d pp. Consequently, 
frequency of release, and concentration of ST and IGF-I were lower (P < .05) in GRFi than in HSAi 
cows. Concentrations of ST increased following FK33-824 in HSAi, but not in GRFi cows. Across 
experiments, interval from calving to ovulation (estimated from weekly progesterone concentrations) 
was greater in HSAi than in GRFi cows. In conclusion, gestating-lactating beef cows were effec­
, tively immunized against GRF as evidenced by antibody binding of [125I]GRF, absence of pulsatile 
release of ST, low concentrations of ST and IGF-I and failure of ST to increase after IV opioid ago­
nist or arginine. 
INTRODUCTION 

Somatotropin (ST) plays an important role in regulating metabolic changes necessary for 
growth (I, 2) and lactation (3). Exogenous ST enhances retention of nitrogen (4), increases 
body weight gain in growing ruminants (1) and increases milk yield in dairy cows (3). 
During lactation in the pig and cow, suckling causes an increase in circulating prolactin and 
ST and a decrease in luteinizing hormone (LH, 5-9). 
Release of ST is regulated by a dual system of hypothalamic peptides in which growth 
hormone-releasing factor (GRF) stimulates (10-11) and somatostatin inhibits (12) release 
of ST. In the pig, suckling increases ST (7) and decreases LH (5-6) through an increase in 
endogenous opioid peptides mediated by the hypothalamus. Opioid agonists cause an in­
crease in ST and a decrease in LH in non-lactating ruminants (13-14), whereas naloxone, 
an opioid antagonist, increased serum LH in lactating cows (9). A paucity of information 
exists concerning factors controlling ST release during lactation in the beef cow. 
Previously, we demonstrated that active immunization against growth hormone releas­
ing factor [GRF-(1-29)-(GlY)4-Cys-NH2] abolished episodic release of ST and decreased 
serum insulin-like growth factor I (IGF-I) in cycling gilts (15) and prepubertal heifers (16). 
We reasoned that this approach would provide an excellent model for evaluating control of 
ST during lactation as well as provide a model for future investigation of the interaction 
between metabolism and reproduction in the postpartum beef cow. The objective of this 
experiment was to determine whether gestating-lactating beef cows could be actively im­
munized against GRF and to determine the effects of immunization on concentrations of ST 
and IGF-I. In addition, we tested the hypothesis that an opioid agonist would increase ST 
in control, but not in GRF-immunized cows (15), whereas we hypothesized that naloxone 
would decrease ST in both GRF-immunized and control cows as previously reported for 
lactating sows (7). 
MATERIALS AND METHODS 
Experiment 1: Six mUltiparous Hereford cows (523 ± 23 kg) were used to determine 
whether beef cows could be actively immunized against GRF and to determine the effect 
of immunoneutralization of GRF on concentrations of ST and IGF-I. Cows were randomly 
assigned to be immunized against GRF conjugated to human serum albumin (n=3) or 
human serum albumin alone (n=3). Primary immunization was administered 52 ± I d 
prepartum by injecting 2 mg GRF analog [GRF(1-29)-(GlY)4-Cys-NH2] conjugated to 2 mg 
human serum albumin (GRFi) or 2 mg human serum albumin (HSAi) emulsified in 
Freund's complete adjuvant. The antigen used was developed for conjugation at the 
carboxyl terminus of human serum albumin. Conjugation was performed using the 
m-maleimido benzoyl-N-hydroxysuccinimide procedure (17). Boosters of appropriate 
antigen (1 mg) emulsified in Freund's incomplete adjuvant were administered on days 
12 ± 1,40 ± 1, and 114 ± I postpartum (pp). Blood samples were collected via venipuncture 
at the time of booster and one week later for determination of antibody production. Immu­
nizations and subsequent boosters were emulsified in a 1: I ratio with Freund's complete or 
incomplete adjuvant (Sigma Chemical Co., St. Louis, MO), respectively, and administered 
as 4 to 5 subcutaneous injections dorsal to the udder. 
During gestation, cows were allowed free access to fescue pasture and supplemented with 
trace mineral salt blocks. During lactation, cows were fed alfalfa hay free choice. 
Body weight was recorded every 2 wks and blood samples were collected at weekly in­
tervals during lactation. Samples were analyzed for GRF antibody and progesterone con­
centrations. Onset of ovulation was estimated to occur when progesterone concentrations 
greater than 1 ng/ml were sustained for 2 wks. 
During lactation, milk consumption by calves (kg/d) was estimated by weigh-suckle-weigh 
beginning on day 86 pp and continuing at 1 to 2 wk intervals until day 137 pp. Calves were 
separated from their dams for 8 hr, weighed, allowed to nurse and weighed again. The dif­
ference in body weight (BW) was multiplied by 3 to estimate daily consumption. 
On days 18, 46 and 120 pp (l week after each booster) cows were non-surgically 
cannulated by inserting a cannula into the jugular vein through a 12 gauge needle and se­
curing the cannula to the skin with elastic tape. The next day, blood samples were collected 
every 15 minutes for a period of 9, 13.5 and 14 hr on days 19.47 and 121, respectively. 
Calves were allowed to nurse during the sampling intervals. Samples obtained over the ~fIrst 
5 hr were used for determination of concentrations of ST. An opioid agonist [(D­
Ala2,MePhe4,Met(0)5-0 1)-enkephalin, FK33-824; 10 I-ig/kg; 18] and an antagonist 
(naloxone; .5 mg/kg) were administered (IV) at hr 5 and 7, respectively. Efficacy ofimmu­
nization against GRF was further tested by administration of a GRF-analog ([desamino­
Tyr1, D-Ala2, Ala15] GRF (l-29)NH2; 3.5 j.lg/kg; 19, 20) (IV) on day 47 at hr 10 and 
injection (IV) of arginine (.5 g/kg) at hr 10 on day 121. 
Blood samples were stored at 4 C for approximately 18 hr, centrifuged at 1,500 g for 30 
minutes and serum decanted and stored at -20 C until assayed. All samples were analyzed 
for ST, and samples collected pre- and post-naloxone (on days 19 and 47 only) were ana­
lyzed for LH. Selected samples (3 hr intervals) were analyzed for IGF-1. 
Experiment 2: Based on results in Experiment 1, a second experiment was conducted 
to determine if a lower dose of antigen and a single booster would produce similar effects 
on ST and IGF-1. Gestating multiparous Hereford and Angus cows (581 ± 30 kg) were ran­
domly assigned to GRFi (n=6) or HSAi (n=6). Primary (1.2 mg) and booster (.5 mg) im­
munizations were administered as described in Experiment 1, approximately -14 and 8 d 
postpartum, respectively. 
Within 1 week after parturition, both cow and calf were moved to an open-sided barn and 
placed in a pen (4 x 7 m) equipped with 12 calan gates. Two calves were born dead; Hol­
stein calves were substituted within 24 hr after calving. 
Cows were restricted in intake of energy during lactation in order to elevate concentra­
tions of ST, because restriction of feed intake increases concentrations of ST in ruminants 
(21). The diet was formulated to provide 60% of recommended energy intake while keeping 
crude protein, calcium, phosphorus and vitamin A at 100% of NRC requirements (22). 
On days 26, 50, 73, 90 and 109 pp (SE = .3) blood samples were collected at 15-min 
intervals for 6 hr from all cows to quantify concentrations of ST and IGF-1. On days 27, 51, 
91 and 110, HSAi (n=3) and GRFi (n=4) cows were given naloxone and subsequently 
FK33-824. Samples were collected at 15-min intervals for 6.5 hr. Naloxone was adminis­
tered (IV) at a dose of .5 mg/kg at 30 and 90 min, since in Exp. 1 a single injection of 
naloxone failed to decrease serum ST. At 270 min, cows were administered FK33-824 (10 
j..1g/kg). Cannulation, blood sampling and processing procedures were similar to that de­
scribed in Experiment 1. Calves were not allowed to nurse during sampling. 
Milk consumption by calves and onset of ovulation were determined as described for 
Exp. 1. Milk consumption was estimated every 2 wks from days 64 to 110 pp. 
In both Experiments, cows were acclimated to halters during gestation. Cows were ob­
served for signs of distress during each sampling interval. Throughout Experiment 1, signs 
of distress were not noted and cows remained haltered throughout each sampling interval. 
On days 26, 27, 50 and 51 of Exp. 2, both GRFi and HSAi cows were restless and pulled 
against their halter throughout the sampling interval. Consequently, samples were collected 
on days 73, 90, 91, 109 and 110 from cows while housed in individually-partitioned, sta­
tionary alleys (1.8 x .7 m). Visible signs of distress were not observed in this environment. 
Single samples were analyzed for cortisol on days 26, 50, 73, 90, and 109 in Experiment 
2, only. 
Assays: Antibody binding against GRF was determined by incubating diluted serum 
(1 :100 to 1: 16,000) with 1251-GRF as described by Armstrong et al (15). Binding at 50% 
was not achieved at any dilution; therefore, antibody concentration was expressed as per­
centage bound at a 1:100 and 1:1,000 dilution in Experiments 1 and 2, respectively. 
Serum ST was measured by radioimmunoassay procedures validated by Armstrong and 
Spears (23). For Experiment 1, intra- and inter-assay CV for 3 assays were 9.5% and 
13.0%, respectively. Assay sensitivity, defined as 90% bound, was 1.5 ng/ml. Intra- and 
inter-assay CV for 8 assays for Experiment 2 were 7.9% and 13.0%, respectively; assay 
sensitivity was 0.6 ng/m!. 
Concentrations of LH were estimated as previously described (23, 24). Intra- and inter­
assay CV for 3 assays in Experiment 1 were 7.4% and 14.6%, respectively. Assay sensi­
tivity was .4 ng/ml. 
Serum IGF-I was assayed using glycylglycine hydrochloride extraction procedures as 
described (25) with modifications (26, 27). The standard source was recombinant human 
IGF-I (Amgen, Thousand Oaks, CA). Anti-IGF-I rabbit serum (UBK487) was obtained 
from Drs. L. Underwood and J. Van Wyk (Univ. North Carolina, Chapel Hill, NC) through 
the National Hormone and Pituitary Program and the NIDDK. Average intra-assay coeffi­
cient of variation was 6.3% for Experiment 1 and 2.8% for Experiment 2. Assay sensitiv­
ity, defined as 90% bound was 9.0 ng/ml. 
Progesterone and cortisol were determined by a solid-phase radioimmunoassay (Diagnos­
tic Products Corp., Los Angeles, CA). Assay sensitivity was 0.1 ng/ml and 3.3 ng/ml for 
progesterone and cortisol, respectively. Progesterone intra-assay CV for experiment 1 and 
2 was 7.9% and 7.2%, respectively. Cortisol intra-assay CV for Experiment 2 was 1.8%. 
Statistical Analyses: All analyses were performed using general linear models proce­
dures (28). Hormone data were analyzed using a model consisting of treatment, cow within 
treatment, day, treatment x day, day x cow within treatment, time, time x treatment, time 
x treatment x day. The effect of treatment was tested using the cow within treatment mean 
square as the error term. Effects of day and treatment x day were tested using the day x cow 
within treatment mean square as the error term. For days from calving to elevated proges­
terone only, Exp. 1 and 2 were combined. The model included treatment, experiment and 
experiment x treatment. 
Episodes of ST release were identified as samples greater than the mean plus one stan­
dard deviation for that sample period; the amplitude of the peak (concentration of the peak 
minus the concentration of the preceding nadir) had to be greater than the assay sensitiv­
ity and the peak concentration had to be at least 50% greater than the previous nadir. Basal 
ST was determined as average ST after episodes of ST were deleted. 
RESULTS 
Experiment 1: Antibody binding against GRF, expressed as percentage binding at I: 100 
dilution, for GRFi and HSAi cows is presented in Figure 1. Within 28 d after primary im­
munization, binding increased (P < .01) in GRFi cows from <2 to 14.3 ± 4.9%, while bind­
ing in HSAi cows was low (0.7 ± 0.3%) throughout the experiment. Percentage binding 
increased (P < .01) in GRFi cows after the first booster, but did not increase (P > .50) af­
ter the second and third booster. 
Mean ST concentrations on days 19,47, and 121 pp were lower (P < .05) in GRFi than 
in HSAi cows (Table 1). Pulsatile release of ST was abolished (P < .01) in GRFi cows on 
all days postpartum. A treatment x day interaction was detected for basal ST due to ST be­
ing lower in GRFi than in HSAi cows on day 47, but not on days 19 and 121 (Table 1). 
Concentrations of IGF-I were lower (P < .05) in GRFi than in HSAi cows on days 19, 
47 and 121 pp (Figure 2). In HSAi cows only, serum IGF-I concentrations were greater (P 
< .05) on days 19 and 47 pp than on day 121 pp. 
Concentrations of ST failed to increase after administration of FK33-824 in GRFi cows 
on days 19,47 or 121 pp (Figure 3). On day 19, concentrations of ST in HSAi cows failed 
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Figure 1. Mean (± SE) percentage binding of (, 251) GRF(1-29)NH, at a 1: 100 dilution of serum from cows immunized against 
GRF conjugated to HSA (GRFi) or HSA alone (HSAi). Primary immunization was given on day -52 from calving. Booster 
doses were injected on days 12.40 and 114 postpartum (Exp. I). 
70 
-
60 
E 
a 
50 
c 40 
I 30 
II.. 
20
'" 
10 
0 
12119 47 
E3 HSAi 
II GRFi 
Days Postpartum 
Figure 2. Mean ± SE concentrations of IGF-I on days 19.47 and 121 postpartum in GRFi and HSAi cows. Serum IGF-I 
concentrations were lower (P < 0.05) in GRFi than in HSAi cows on all days postpartum. Days postpartum affected IGF-I 
in HSAi (P< 0.05), but not in GRFi cows (Exp. 1). 
TABLE 1. EFFECT OF IMMUNIZATION AGAINST GRF CONJUGATED TO HSA (GRFI) OR HSA ALONE (HSAI) ON 

FREQUENCY OF RELEASE AND CONCENTRATIONS OF SOMATOTROPIN (ST) (Exp. 1). 

Episodic ST 

Mean ST (ng/ml) (peaks/5 hr) Basal ST (ng/m]) 

Days Postpartum 
HSAi GRFi HSAi GRFi HSAi GRFi 
19 6.7 ± Oo4a,b 404±0.1 1.3 ± 0.3b 0.0 ± 0.0 5.0 ± 0.6C 404 ± 0.2 
47 11.0 ± 1.1b 3.7 ± 0.1 2.0 ± 0.6b 0.0 ± 0.0 6.0 ± 0.2 3.7 ± 0.3 
121 8.6 ± 0.7b 4.0 ±0.2 2.0 ± 0.6b 0.0 ± 0.0 4.3 ± 0.2 3.8 ± 0.4 
aMean± SE. 
bHSAi different from GRFi cows, P < 0.05. 
CTreatment by days postpartum, P < 0.05. 
to increase after FK33-824 (Figure 3, upper panel); however, on days 47 and 121 pp, con­
centrations of ST 60 minutes after FK33-824 were greater (P < .05) than concentrations 
prior to FK33-824 (Figure 3, middle and lower panel). 
Concentrations of ST for both treatment groups were not affected (P > .20) by naloxone 
on any sample day (data not presented). Naloxone increased (P < .05) concentrations of LH 
in HSAi and GRFi cows on day 47 pp; however, LH did not increase after naloxone on day 
19 pp (Figure 4). 
Administration of a GRF-analog on day 47 pp increased (P < .01) concentrations of ST 
in both treatment groups when compared to concentrations prior to GRF-analog. Concen­
trations of ST at 15 minutes after GRF-analog were similar (P > .20, Figure 5) in GRFi and 
HSAi cows; however, concentrations of ST from 60 to 210 minutes were lower (P < .01) 
in GRFi than in HSAi cows. Administration of arginine increased ST in HSAi, but not in 
GRFi cows. Average concentrations of ST (ng/ml) 30 to 90 minutes after arginine were 
greater (P <.01) in HSAi than in GRFi cows (Figure 6). 
Average milk consumption (kg/d) by calves on days 86 and 96 was greater (P < .05) in 
HSAi (6.6 ± .7) than in GRFi (3.2 ± .5) cows; however, consumption on days 115, 131 and 
137 was similar in HSAi (3.8 ± .7) and GRFi (3.2 ± .7) cows. In contrast, ADG of calves 
was not affected by treatment (data not presented). 
Weight change (kg) of cows from -52 to 74 d pp was lower (P < .05) in HSAi (-15 ± 0.6) 
than in GRFi (-4 ± 4.9) cows. Interval from calving to elevated progesterone (>1 ng/ml) 
tended (P=.12) to be greater in HSAi (72 ± 9 d) than in GRFi (53 ± 0) cows. 
Experiment 2: Two of six GRFi cows failed to respond to GRFi as evidenced by anti­
body binding «10% at a 1:1,000 dilution of serum) and release of ST at a frequency similar 
to control cows. All data from these two cows were deleted from subsequent analyses. 
Antibody binding to 125I-GRF(1-29)NH2, expressed as percentage binding at 1:1,000 di­
lution, is presented in Table 2. At the time of primary immunization, percentage binding 
was very low in all cows; thereafter binding increased in GRFi but not in HSAi cows, par­
ticularly at 21 d after booster immunization (day 29 pp). 
Concentrations of ST on days 26, 50, 73, 90, and 109 pp are presented in Table 3. Con­
centrations of ST were lower (P < .05) in GRFi than in HSAi cows on all days postpartum. 
Mean ST in HSAi cows was greater on days 26 and 50 than on days 73, 90 and 109 pp 
(Table 3, Figure 7). This difference was associated with outward signs of distress in GRFi 
and HSAi cows; however, concentrations of ST increased during the sampling interval in 
HSAi, but not in GRFi cows (Figure 7). Concentrations of cortisol (ng/ml) across all days 
pp were low and similar in GRFi (8.0 ± 1.5) and in HSAi (7.6 ± 1.5) cows. 
Pulsatile release of ST (Table 3) was not different from zero in GRFi cows on all days 
pp and was less (P < .01) than the frequency of ST release in HSAi cows. In HSAi cows, 
frequency of ST release did not vary with days pp. Basal ST was greater in HSAi than in 
GRFi cows on all days sampled; however, this difference was significant only on days 26 
and 50 pp, only. 
Concentrations of IGF-I in GRFi and HSAi cows are depicted in Figure 8. Serum IGF­
I was lower in GRFi than in HSAi cows on all days pp. 
The opioid agonist, FK33-824, significantly increased ST in HSAi, but not in GRFi 
cows, on all days pp. Serum ST increased following FK33-824 similarly on all days pp in 
HSAi cows, thus, concentrations of ST were pooled across days pp (Figure 9). Concentra­
tions of ST were not altered (P> .2) by two injections of naloxone (data not presented). 
Consumption of milk by calves was not affected by treatment in Exp. 2. Milk consump­
tion (kg/d) averaged across days 78, 92, 106 and 130 was similar in HSAi (7.2 ± 1.2) and 
GRFi (6.0 ± 1.2) cows. In addition, ADG was similar in calves nursing dams immunized 
against GRF or HSA (data not shown). 
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Figure 3. Mean (± SE) ST from -30 to 120 min from administration (IV) of FK33-824 (opioid agonist. 10 )lg/kg BW) on days 
19,47 and 121 postpartum in cows immunized against GRF conjugated to HSA (GRFi) or HSA (HSAi). Serum ST increased 
on days 47 and 121 but not on day 19 postpartum in HSA cows only (P < 0.05). Serum ST did not increase (P > 0.2) after 
FK33-824 in GRFi cows (Exp. 1). 
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Figure 4. Concentrations of LH (mean ± SE) from -45 to 90 min from administration of naloxone in GRFi and HSAi cows 
on days 19 and 47 postpartum. Serum LH was similar (P > 0.2) in GRFi and HSAi cows, thus data were pooled. Naloxone 
increased LH on day 47 (P < 0.05) but not on day 19 postpartum (Exp. 1). 
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Figure 5. Average (± SE) ST concentrations from -30 to 210 min from administration of a GRF-analog on day 47 postpartum 
in GRFi and HSAi cows. ST increased (P < 0.05) following GRF-analog in both treatment groups but remained elevated 
throughout the remainder of the sampling period in HSAi cows only (Exp. 1). 
Change in BW (kg) of cows from -13 to 73 d pp was similar in GRFi (-21 ± 5) and HSAi 
(-24 ± 4) cows. Interval from calving to ovulation, estimated by elevated progesterone (> 
1.0 ng/ml), tended to be greater (P<.12) in HSAi (62 ± 8 d) than in GRFi (44 ± 6 d) cows. 
Analysis across experiment (or year) revealed that treatment, but not experiment or treat­
ment x experiment, contributed (P<.05) to variation in days from calving to ovulation. In­
terval from calving to elevated progesterone was lower in GRFi (48 ± 4, n=7) than in HSAi 
(65 ± 6, n=9) cows. 
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Figure 6. Mean (± SE) ST level on day 121 postpartum from -30 to 120 min from arginine in cows immunized against GRF 
conjugated to HSA (GRFi) or HSA (HSAi). Concentrations of ST increased (P < 0.05) after arginine in HSAi but not in GRFi 
cows (Exp. 1). 
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Figure 7. Concentrations of ST on days 26, 50. 73. 90 and 109 postpartum in HSAi and GRFi cows. ST was not affected by 
day postpartum in GRFi cows, thus data were pooled across day. Serum ST was lower (P < 0.05) in GRFi than in HSAi on 
all day postpartum. Serum ST was greater (P < 0.05) in HSAi cows on days 26 and 50 than on days 73, 90 and 109 (Exp. 2). 
TABLE 2. PERCENTAGE BINDING OF SERUM FROM Cows IMMUNIZED AGAINST GRF CONJUGATED TO 

HSA CORF!) OR HSA ALONE (HSAI) (Exp. 2). 

---0--- GRFi 
120 180 240 
Time in Minutes 
Percentage Binding at I: 1000 Dilution 
Days Postpartum GRFi HSAi 
-13 0.5 ± 0.3b 0.2 ± 0.2 
8a 1.0 ± 0.7c <0.2 
29 1O.0± 3.6c <0.2 
89 17.0 ± 4.7c 1.4±0.4 
"Booster administered at 8 ± 4 d postpartum. 

"Mean ± SE. 

cGRFi vs HSAi, P < 0.05. 
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TABLE 3. EFFECT OF ACTIVE IMMUNIZATION AGAINST GRF CONJUGATED TO HSA 
(GRFI) OR HSA ALONE (HSAI) ON ST (Exp. 2) 
Treatment 
Day postpartum GRFi 	 HSAi 
Mean ST (ng/ml) 
b26 0.6 ± O.l a• 3.5 ± 0.2 
50 0.6±0.lb 3.9 ± 0.3 
73 	 0.6 ± O.lb 2.2 ± 0.1 
90 	 0.7 ± O.lb 1.9 ± 0.1 
109 	 0.8±0.lb 1.9 ± 0.1 
ST peaks per 6 hr 
26 	 0.0 ± O.Ob 2.7 ± 0.1 
50 	 0.3 ± 0.3b 3.3 ± 0.1 
73 	 0.0 ± O.Ob 2.7 ± 0.6 
90 0.3 ± 0.3b 2.8 ± 0.4 
109 0.0 ± O.Ob 2.3 ± 0.4 
Basal ST (ng/ml) 
26 0.6±0.lb 1.9 ± 0.1 
50 	 0.6 ± O.lb 1.7 ± 0.1 
73 	 0.6 ± 0.1 1.3 ± 0.1 
90 0.6 ± 0.1 1.3 ± 0.3 
109 0.8 ± 0.1 1.2 ± 0.2 
"Mean ± SE. 

bGRFi vs HSAi, P < 0.05. 
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Figure 8. Mean (± SE) IGF-I concentrations in GRFi or HSAi cows. GRFi cows had lower (P < 0.05) IGF-I concentrations 
than HSAi cows (Exp. 2). 
28 
24 
20 
E 
0) - 16s:::: 
12
..: 
en 8 
4 
0 
• GRFi 
-0-- HSAi 
- 3 0 - 1 5 o 1 5 30 45 60 75 90 1 05 
Minutes from FK33-824 
Figure 9. Concentrations of ST (± SE) averaged over days 27, 51, 91 and 110 postpartum in GRFi (n=4) and HSAi (n=3) cows 
from -30 to 105 min post FK33-824 injection. Within treatment, change in ST following FK33-824 was similar across days 
postpartum, thus data were pooled. Concentrations of ST increased (P < 0.05) in HSAi cows but not in GRFi cows after FK33­
824 (Exp. 2). 
DISCUSSION 
Lactating beef cows were successfully immunized against GRF as evidenced by the pres­
ence of GRF antibodies, absence of pulsatile release of ST, decreased serum IGF-I and the 
failure of an opioid agonist or arginine to increase ST in cows immunized against GRF. 
Similar results were observed with passive immunization against GRF in rats (29, 30) and 
active immunization against GRF in pigs (IS), steers (31) and heifers (16). Results from 
Exp. 2 reveal that one booster following a primary immunization is sufficient to suppress 
pulsatile ST and circulating IGF-I through 100 d postpartum. 
In both experiments, antibody binding did not achieve SO% at any assay dilution. In con­
trast, prepubertal beef heifers (16) and gilts (IS) actively immunized against GRF achieved 
titers (dilutions required to bind SO% of radiolabeled-GRF) ranging from 1: 11,000 to > 
1:60,000. Antibody binding in Exp. 1 and 2 was sufficient to abolish episodic release of ST 
in all GRF-immunized cows. Two GRF-immunized cows in Experiment 2 displaying pul­
satile release of ST had binding of 10% or less at a 1: 1000 dilution, thus data were omit­
ted from other analyses. The seven remaining GRFi cows with abolished episodic release 
of ST (Exp. 1 and 2) had antibody binding ranging from 10% to 35% at either a 1:100 or 
1: 1000 dilution. 
Immunoneutralization of GRF decreased mean ST concentrations by obliterating pulsa­
tile release of ST and decreasing basal ST. Techniques used to study the role of GRF regu­
lation on ST secretion such as hypothalamic deafferentation (32), hypothalamic 
ventromedial lesions (33) or hypophyseal stalk transection (34, 3S) have demonstrated simi­
lar decreases in ST episodic secretion. However, basal concentrations of ST in Klindt and 
coworkers study (3S) were elevated after hypophyseal stalk transection possibly due to a 
decreased amount of somatostatin reaching the pituitary gland. 
Serum concentrations of ST were lower in GRF-immunized cows, primarily due to a lack 
of pulsatile release of ST, and this was associated with lower concentrations of IGF-I in 
both experiments. Hypophysectomy in pigs (36) and active immunization against GRF in 
heifers (16), steers (31) and pigs (15) were also associated with decreased serum IGF-I. 
Hannon et at. (37) recently reported that liver IGF-I mRNA and liver IGF-I production were 
significantly correlated with amplitude of ST release in beef cattle. 
Administration of a GRF-analog increased ST in GRF- and HSA-immunized cows in 
Experiment 1. Cows immunized against HSA alone maintained elevated ST concentrations 
for the duration of blood sampling (210 minutes post GRF-analog) similar to that in pre­
vious reports utilizing GRF(l-29)-NH2 in heifers and pigs (38, 39). However, the response 
observed in GRFi cows was abrupt and short-lived when compared to HSAi (control) cows. 
In contrast to our results, Armstrong et al (15) and Simpson et al (16) observed that anti­
bodies against GRF cross-reacted with GRF analog as evidenced by the inability of the 
GRF analog to stimulate ST in pigs pr heifers immunized against GRF. The discrepancy 
between results of the present study and the aforementioned studies (15,16) is likely related 
to the greater antibody levels. Comparing the present results with Armstrong et al (15), 
different antibody epitopes are not indicated, as both cow and pig antibodies similarly bind 
[1 251] GRF-analog (R. M. Campbell, unpublished observation). 
Infusion of arginine increased ST concentrations in HSAi but not in GRFi cows (Experi­
ment 1). Arginine has been shown to elevate ST levels in sheep (40), cows (41) and pigs 
(42). Since GRFi cows did not respond to arginine, it would seem that the mechanism of 
action of arginine-induced ST secretion involves release of hypothalamic GRF. This is in 
agreement with Anderson et al (42)~ they reported that stalk transection blocked the stimu­
latory effect of arginine on ST in pigs. However, in vitro studies using rat pituitary cells 
indicated that arginine administration stimulated ST release by inhibiting somatostatin re­
lease from the hypothalamus (43). Thus, a synergistic effect of arginine involving GRF and 
somatostatin cannot be excluded. 
Based on the consistency of these results, it appears that opioid peptides stimulate ST in 
the cow through stimulation of GRF. Administration of an opioid agonist, FK33-824, failed 
to increase ST in GRFi cows, whereas injection of FK33-824 in HSAi cows was followed 
by an episode of ST release on all days postpartum except for day 19 ± I pp in Exp. 1. 
Passive immunization against GRF abolished increases of ST following l3-endorphin (44), 
morphine (30) or FK33-824 (45). Active immunization against GRF in pigs (15) or heif­
ers (16) had similar results. Also, a stimulatory effect of opioid peptide agonists on ST has 
been demonstrated in rodents (46), sheep (14) and heifers (13, 16). 
We were surprised that administration of naloxone, an opioid antagonist, did not decrease 
concentrations of ST in either GRFi or HSAi cows on any day postpartum in Exp. 1 or 2. 
Other reports have demonstrated that naloxone decreased ST in the suckled rat (47) and pig 
(7). Naloxone was apparently present in sufficient quantities on day 47 (Exp. 1) to interact 
with opioid receptors, because naloxone increased LH in all heifers on day 47. The dosage 
of naloxone may have been inadequate to decrease ST on day 19 because concentrations 
of LH failed to increase after naloxone and ST failed to increase after FK33-824 on day 19. 
Similar increases in LH after naloxone were reported for postpartum women (48) and post­
partum beef cows (9). Whisnant and coworkers (9) observed that challenges of naloxone 
stimulated LH release on days 28 and 42, but not on day 14 postpartum. We cannot explain 
why naloxone increased LH but failed to decrease serum concentrations of ST on day 47, 
but previous reports have demonstrated that opioid receptor agonists such as FK33-824 bind 
preferentially but not exclusively to mu receptors rather than the native enkephalin delta 
receptors (49). The existence of various opioid binding sites may provide a logical assump­
tion for differences seen in endocrine responses to naloxone. Therefore in the lactating cow, 
a larger dose and(or) infusion of naloxone may be required for blockage of the opioid re­
ceptor regulating GRF secretion so that attenuation of ST can be observed. 
The failure of FK33-824 to increase ST and that of naloxone to increase LH on day 19 
pp, whereas similar treatments on day 47 pp increased ST and LH, indicates a change in 
opioid sensitivity may have occurred between days 19 and 47 postpartum. This change in 
sensitivity in ST in response to FK33-824 was not observed, however, in Exp. 2. Several 
differences between Exp. 1 and 2 (location, year, diet - hay vs silage, breed) render this 
question unanswerable. However, it is interesting to note that serum IGF-I concentrations 
were affected by day pp in Exp. 1 but not in Exp. 2. 
Apparent distress associated with sampling in Exp. 2 coincided with elevated concentra­
tions of ST. Cortisol levels, however, were low and not different between treatment groups. 
Milk consumption by calves and cow weight loss were apparently affected by treatment 
in Exp. 1, but not Exp. 2. The effect of treatment on milk consumption was transient in Exp. 
1 particularly since ADG of calves was not altered. A decrease in milk yield and, thus a 
decrease in energy necessary for milk synthesis, is consistent with the homeorrhetic effects 
of ST in ruminants (3, 50, 51). 
Immunization against GRF tended to hasten onset of ovulation in Exp. 1 and 2. In Exp. 
1 only, this difference was associated with differences in cow BW change. As reviewed by 
Randel (52) and Short (53), cows losing less weight postpartum would be expected to have 
an earlier resumption of estrous cycles. However, in both Exp. 1 and 2 serum IGF-I was 
lower in GRFi than in HSAi cows. This is in contrast to studies by Simpson in that primipa­
rous cows (54) and heifers (16) with lower serum IGF-I had greater intervals from calving 
to elevated progesterone (54) and age at puberty (16). Additional studies are needed to 
clarify the relationship among metabolism, serum IGF-I and ovarian function. 
We cannot explain why GRFi altered milk consumption of calves and cow weight 
change in Exp. 1 but not in Exp. 2. However, several explanations are possible. In addition 
to differences in breed, year and location, a major difference was that cows in Exp. 2 were 
restricted in feed intake. As expected, cow weight change was greater in Exp. 2 than in 1. 
It is possible that the homeorrhetic effects of ST vary with nutritional status of the cow. 
Additional studies are necessary to investigate this possibility. 
In conclusion, gestating-lactating beef cows were successfully immunized against growth 
hormone-releasing factor as measured by presence of antibodies against GRF, abolishment 
of episodic release of ST and suppressed concentrations of IGF-1. Failure of a GRF analog, 
an opioid agonist and arginine to stimulate ST verified the completeness of the immuno­
neutralization and provide strong evidence that opioid peptides and arginine increase serum 
ST through a mechanism primarily involving GRF. Immunoneutralization against GRF 
provides an effective model to evaluate factors regulating ST in the cow. 
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